A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Trial Profile

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs V 212 (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 23 May 2018 Results asessing health utilities and health care costs in auto-HSCT recipients presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 08 Oct 2017 Results of exploratory analysis assessing immunogenicity of the varicella zoster virus vaccine V 212 in autologous hematopoietic cell transplant recipients for the prevention of herpes zoster, were presented at the IDWeek 2017.
    • 04 Oct 2017 According to a Merck & Co media release, new data analysis from the study will be presented at ID Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top